T1	Participants 66 130	patients with chemotherapy-induced painful peripheral neuropathy
T2	Participants 536 659	231 patients who were 25 years or older being treated at community and academic settings between April 2008 and March 2011.
T3	Participants 896 1157	patients have grade 1 or higher sensory neuropathy according to the NCI Common Terminology Criteria for Adverse Events and at least 4 on a scale of 0 to 10, representing average chemotherapy-induced pain, after paclitaxel, other taxane, or oxaliplatin treatment
